The Chinese Colorectal Cancer Market Will Grow Rapidly Over the Next Five Years, Increasing from Approximately $360 Million in 2012 to $575 Million in 2017 Rapid Expansion of Drug-Treatable Population and Increasing Uptake of Premium-Priced Biologics Will Drive Market Growth, According to Findings from Decision Resources
BURLINGTON, Mass., Dec. 12, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that, from 2012 to 2017, the colorectal cancer (CRC) market in China will grow at an annual rate of 9 percent, reaching approximately $575 million in 2017. Decision Resources' new special report entitled Colorectal Cancer in China finds that the rapidly growing CRC patient population, increasing uptake of premium-priced biologics, as well as expanding reimbursement coverage of CRC agents will promote growth in this market.
Between 2012 and 2017, three novel CRC therapies will launch in China—Amgen/Takeda's Vectibix, Sanofi's Zaltrap and Bayer HealthCare's Stivarga. Although the number of patients treated with these agents will be smaller than that of the major markets—because of the agents' later launch dates, high price and the reimbursement constraints of the Chinese market—these therapies will together contribute 3 percent to the total CRC market in 2017.
The report also finds that the number of incident cases of CRC in urban China will almost double between 2012 and 2022, mainly due to an increase in disease risk as well as due to changes in the population structure (i.e. an increase in the proportion of people in the older, high-risk age groups within the population and an increase in total population size).
"Chemotherapy agents will continue to dominate the Chinese CRC market through 2017, and targeted biological agents currently have relatively small patient shares when treating metastatic CRC patients. However, we expect that Roche's Avastin will become the brand and overall sales leader in the CRC therapeutic market in 2017," said Decision Resources Analyst Youling Guo, Ph.D. "Price cuts, generic erosion and reimbursement constraints will continue to negatively impact the Chinese CRC market. Price cuts in particular have played a critical role in constraining the market in the past, and we expect a further decline in pricing of all branded and generic agents to occur by the end of 2017."
The new report features extensive primary research with Chinese oncologists as well as a market outlook through 2017.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or
registered trademarks of their respective holders.
For more information, contact:
SOURCE Decision Resources